News

  • Feb
    09
    2021

    Broadway Belts for PFF! Goes Virtual

    Broadway stars on a mission to raise funds and awareness for pulmonary fibrosis (PF) will take the stage virtually for the first time in the Pulmonary Fibrosis Foundation’s (PFF) 11th annual Broadway Belts for PFF! on Friday, March 12, at 7 p.m. ET.
    Read Full Article Broadway Belts for PFF! Goes Virtual
  • Jan
    14
    2021

    Pulmonary Fibrosis Foundation Announces Sponsorship by United Therapeutics

    The PFF has announced United Therapeutics’ sponsorship of the PFF Registry, a research resource that tracks clinical data, blood samples and patient-reported outcomes from individuals living with PF nationwide.
    Read Full Article Pulmonary Fibrosis Foundation Announces Sponsorship by United Therapeutics
  • Jan
    11
    2021

    First Patient Enrolls In PRECISIONS Study For Treatment Of Idiopathic Pulmonary Fibrosis

    The Pulmonary Fibrosis Foundation announced enrollment of the first patient in PRECISIONS ​(Prospective tReatment EffiCacy in IPF uSIng genOtype for Nac Selection) clinical trial. This is the first clinical trial to apply the principles of precision medicine to the treatment of patients with idiopathic pulmonary fibrosis (IPF).
    Read Full Article First Patient Enrolls In PRECISIONS Study For Treatment Of Idiopathic Pulmonary Fibrosis
  • Dec
    23
    2020

    The Importance of SARS-CO-V-2 Vaccination to Prevent COVID-19 and its Impact in the Pulmonary Fibrosis Community

    In accordance with Recommendations issued by the Centers for Disease Control and Prevention, the Pulmonary Fibrosis Foundation strongly encourages vaccination for COVID-19, as the benefits far outweigh the risks. The two authorized vaccines have been demonstrated to be safe and extremely effective in preventing COVID-19 and/or limiting the development of severe COVID-19.
    Read Full Article The Importance of SARS-CO-V-2 Vaccination to Prevent COVID-19 and its Impact in the Pulmonary Fibrosis Community
  • Dec
    10
    2020

    Pulmonary Fibrosis Foundation Chief Medical Officer To Depart For Industry Role

    The Pulmonary Fibrosis Foundation (PFF), the nation’s leading pulmonary fibrosis (PF) education and advocacy organization, announces the departure of Chief Medical Officer (CMO) Gregory P. Cosgrove, MD who will join Pliant Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related disease, as Vice President, Clinical Development (IPF), effective December 31, 2020.
    Read Full Article Pulmonary Fibrosis Foundation Chief Medical Officer To Depart For Industry Role
  • Nov
    23
    2020

    Pulmonary Fibrosis Researcher Wins NIH Award

    The Pulmonary Fibrosis Foundation (PFF) is announcing that 2019 PFF Scholar, Dr. Jeremy Katzen at the University of Pennsylvania, a PFF Care Center Network site, has received a National Institutes of Health (NIH) K08 award.
    Read Full Article Pulmonary Fibrosis Researcher Wins NIH Award